Navigation Links
NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
Date:12/12/2010

company partners, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.  In addition to the releasable polymer technology, Nektar is the first company to create a permanent small molecule-polymer conjugate with enhanced oral bioavailability and restricted entry into the CNS.  Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas.  Nektar recently entered into an exclusive worldwide license agreement with AstraZeneca for its oral NKTR-118 program to treat opioid-induced constipation and its NKTR-119 program for the treatment of pain without constipation side effects.  NKTR-102 is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers.  NKTR-105 is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect Nektar's current views regarding the potential of Nektar's technology platform, the potential of NKTR-102 for breast cancer patients, and preliminary results from the Phase 2 clinical trial of NKTR-102 in metastatic breast cancer.  These forward-looking statements involve substantial risks and uncertainties, including but not limited to one or more of the following: (i) NKTR-102 is in mid-stage clinical development and the risk of failur
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
2. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
10. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... , Aug. 30, 2014   Royal Philips  ... Affiniti, a new ultrasound system designed to ... demands of increasing patient volumes and cost pressures. Making ... 2014 in Barcelona this ... facing more patients with fewer resources deliver high quality ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- Market Research ... Industry, 2009-2019 is a professional and in-depth market ... Scanner industry . The report firstly reviews the ... classification, application and manufacturing technology. The report then ... Crystallography Scanner listing their product specification, capacity, Production ...
(Date:8/29/2014)... 2014  Chuma Holdings, Inc. (OTCBB:CHUM) (the "Company"), ... support services for the lawfully organized cannabis industry, ... approved the Company,s name and symbol change request. ... be known as Chuma Holdings, Inc. ... merger with the Company,s wholly-owned subsidiary, Chuma Holdings, ...
Breaking Medicine Technology:Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3
... 28 The U.S. Food and Drug Administration ... for the treatment of a rare blood cancer ... Philadelphia chromosome positive chronic phase chronic myeloid leukemia ... bone marrow disease linked to a genetic abnormality. ...
... Aethlon Medical, Inc. (OTC Bulletin Board: ... to address infectious disease and cancer, announced today that ... Aethlon Medical.  Aethlon Chairman and CEO, Jim Joyce, previously ... joined Aethlon,s Board of Directors and will retain his ...
Cached Medicine Technology:FDA Approves Additional Medical Indication for Sprycel 2FDA Approves Additional Medical Indication for Sprycel 3Aethlon Medical Names Rod Kenley President 2Aethlon Medical Names Rod Kenley President 3Aethlon Medical Names Rod Kenley President 4Aethlon Medical Names Rod Kenley President 5
(Date:8/30/2014)... "My niece developed a nighttime fever, and I ... fever might get worse," said an inventor from Montgomery, ... how she was doing, I developed this monitoring system." ... a child's temperature. The unit instantly alerts parents if ... medical care can be given, which is designed to ...
(Date:8/30/2014)... 2014 The federal judge overseeing ... http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston Scientific Corp. has ... selected for one of the proceeding’s bellwether trials. ... 2014, U.S. District Judge Joseph R. Goodwin of ... Boston Scientific’s contention that a consolidated trial would ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
(Date:8/30/2014)... 2014 Top10BestSEOHosting.com is a well-known ... announced that HostGator.com http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts is the ... Also, they has announced that Bluehost and Arvixe ... Hostgator, one of the Top 10 Web Hosting ... Windows hosting, and it offers rich features and ...
(Date:8/30/2014)... August 30, 2014 August 28th, 2014: ... pain in our society and the toll that takes ... it’s vital that continuing education for physical therapists addresses ... help physical therapists help others, Hands-On Seminars is offering ... , Three learning styles are available to fit ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Top10BestSEOHosting.com: HostGator.com Is The Best Windows Hosting Supplier 2Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2
... causes bloodstream infections is five times more lethal than other ... potent antibiotic drug vancomycin used to treat MRSA, according to ... 50 percent of the patients infected with the strain died ... with other MRSA strains. The average 30-day mortality ...
... During Last Year,s ,One Million Tests, World AIDS Day ... Testing Goal by Testing 35,034 , PHNOM PENH, Cambodia, ... to test several million people for HIV in observance of ... 2009 campaign, AHF/Cambodia CARES will launch its inaugural testing effort ...
... most seriously ill, experts say , SATURDAY, Oct. 31 (HealthDay ... to double the risk of stroke in patients with diabetes ... a new study finds. , Darbepoetin alfa, marketed as ... prescribed for diabetic patients with chronic kidney disease and mild ...
... Amgen (Nasdaq: AMGN ) today announced the ... Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, ... kidney disease (CKD) not on dialysis, moderate anemia and ... New England Journal of Medicine and presented ...
... Long Beach, CA; December 8, 2009 , NEEDHAM, ... announced that a special event, Terminology Services Information Day, will ... CA USA on December 8, 2009. For more information and ... http://www.omg.org/terminology-services-day . , (Logo: http://www.newscom.com/cgi-bin/prnh/20090629/DC39325LOGO ...
... based in McAllen, Texas, has agreed to pay the United ... False Claims Act, the Anti-Kickback Statute and the Stark Statute ... in order to induce them to refer patients to hospitals ... L.P., d/b/a/ South Texas Health System, is a subsidiary of ...
Cached Medicine News:Health News:Henry Ford Hospital study: A MRSA strain linked to high death rates 2Health News:Cambodia: World AIDS Day HIV Campaign, 'Testing Millions,' to Again Launch During Cambodia's National Water Festival 2Health News:Anemia Drug May Raise Stroke Risk in Kidney Patients 2Health News:Anemia Drug May Raise Stroke Risk in Kidney Patients 3Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 2Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 3Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 4Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 5Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 6Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 7Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 8Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 9Health News:OMG Announces Special Event: Terminology Services Information Day 2Health News:OMG Announces Special Event: Terminology Services Information Day 3Health News:Texas Hospital Group Pays U.S. $27.5 Million to Settle False Claims Act Allegations 2Health News:Texas Hospital Group Pays U.S. $27.5 Million to Settle False Claims Act Allegations 3
Multiple Modulation Phaco (MMP) programmability with eight surgeon settings for maximum versatility. The combination of the peristaltic power balanced pump and the piezoelectric handpiece results in ...
... The Precisionist workstation is a ... operating system allowing infinite flexibility for ... to meet the demands of changing ... A new concept in ophthalmic surgical ...
A gentle yet highly effective corneal rust ring remover with Alger brush of 1mm burr. Runs off 1 x AA battery, no switches, simply spin mandrel to operate....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Medicine Products: